Logo image of CGTX

COGNITION THERAPEUTICS INC (CGTX) Stock Fundamental Analysis

NASDAQ:CGTX - Nasdaq - US19243B1026 - Common Stock

0.74  +0.06 (+8.54%)

Premarket: 0.7664 +0.03 (+3.57%)

Fundamental Rating

2

Overall CGTX gets a fundamental rating of 2 out of 10. We evaluated CGTX against 195 industry peers in the Pharmaceuticals industry. While CGTX seems to be doing ok healthwise, there are quite some concerns on its profitability. CGTX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CGTX has reported negative net income.
In the past year CGTX has reported a negative cash flow from operations.
CGTX had negative earnings in each of the past 5 years.
CGTX had a negative operating cash flow in each of the past 5 years.
CGTX Yearly Net Income VS EBIT VS OCF VS FCFCGTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -10M -20M -30M -40M -50M

1.2 Ratios

The Return On Assets of CGTX (-124.26%) is worse than 81.72% of its industry peers.
The Return On Equity of CGTX (-236.64%) is worse than 73.66% of its industry peers.
Industry RankSector Rank
ROA -124.26%
ROE -236.64%
ROIC N/A
ROA(3y)-47.75%
ROA(5y)-86.04%
ROE(3y)-63.41%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CGTX Yearly ROA, ROE, ROICCGTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 100 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CGTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CGTX Yearly Profit, Operating, Gross MarginsCGTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023

More info and screens

6

2. Health

2.1 Basic Checks

CGTX has more shares outstanding than it did 1 year ago.
CGTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CGTX Yearly Shares OutstandingCGTX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 10M 20M 30M
CGTX Yearly Total Debt VS Total AssetsCGTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of -13.46, we must say that CGTX is in the distress zone and has some risk of bankruptcy.
CGTX's Altman-Z score of -13.46 is on the low side compared to the rest of the industry. CGTX is outperformed by 79.57% of its industry peers.
CGTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -13.46
ROIC/WACCN/A
WACCN/A
CGTX Yearly LT Debt VS Equity VS FCFCGTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 20M 40M

2.3 Liquidity

CGTX has a Current Ratio of 2.11. This indicates that CGTX is financially healthy and has no problem in meeting its short term obligations.
CGTX has a Current ratio (2.11) which is comparable to the rest of the industry.
CGTX has a Quick Ratio of 2.11. This indicates that CGTX is financially healthy and has no problem in meeting its short term obligations.
CGTX has a Quick ratio (2.11) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.11
Quick Ratio 2.11
CGTX Yearly Current Assets VS Current LiabilitesCGTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

More info and screens

0

3. Growth

3.1 Past

CGTX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -22.78%.
EPS 1Y (TTM)-22.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.64%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

CGTX is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 3.60% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-1.29%
EPS Next 2Y5.11%
EPS Next 3Y-12.69%
EPS Next 5Y3.6%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CGTX Yearly Revenue VS EstimatesCGTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M 400M
CGTX Yearly EPS VS EstimatesCGTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CGTX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CGTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CGTX Price Earnings VS Forward Price EarningsCGTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CGTX Per share dataCGTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

A cheap valuation may be justified as CGTX's earnings are expected to decrease with -12.69% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.11%
EPS Next 3Y-12.69%

More info and screens

0

5. Dividend

5.1 Amount

CGTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

COGNITION THERAPEUTICS INC

NASDAQ:CGTX (1/21/2025, 8:00:00 PM)

Premarket: 0.7664 +0.03 (+3.57%)

0.74

+0.06 (+8.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13 2024-11-13/bmo
Earnings (Next)N/A N/A
Inst Owners28.3%
Inst Owner Change0.87%
Ins Owners0.56%
Ins Owner Change0%
Market Cap30.75M
Analysts85.45
Price Target6.63 (795.95%)
Short Float %4.37%
Short Ratio0.2
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)8.12%
Min EPS beat(2)-8.93%
Max EPS beat(2)25.17%
EPS beat(4)2
Avg EPS beat(4)7.88%
Min EPS beat(4)-8.93%
Max EPS beat(4)25.17%
EPS beat(8)5
Avg EPS beat(8)6.56%
EPS beat(12)8
Avg EPS beat(12)-349.28%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.84%
PT rev (3m)4.84%
EPS NQ rev (1m)0%
EPS NQ rev (3m)11.9%
EPS NY rev (1m)0%
EPS NY rev (3m)3.32%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.12
P/tB 2.12
EV/EBITDA N/A
EPS(TTM)-0.97
EYN/A
EPS(NY)-0.77
Fwd EYN/A
FCF(TTM)-0.62
FCFYN/A
OCF(TTM)-0.61
OCFYN/A
SpS0
BVpS0.35
TBVpS0.35
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -124.26%
ROE -236.64%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-47.75%
ROA(5y)-86.04%
ROE(3y)-63.41%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 28.3%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.11
Quick Ratio 2.11
Altman-Z -13.46
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)132.99%
Cap/Depr(5y)116.79%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-22.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.64%
EPS Next Y-1.29%
EPS Next 2Y5.11%
EPS Next 3Y-12.69%
EPS Next 5Y3.6%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-30.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-203.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-209.7%
OCF growth 3YN/A
OCF growth 5YN/A